Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in Arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial

- 4
- Luka Tandaric^{1,2}, Annika Auranen^{3,4}, Katrin Kleinmanns¹, René DePont Christensen⁵, Liv
 Cecilie Vestrheim Thomsen^{1,2,6}, Cara Ellen Wogsland^{1,7}, Emmet McCormack^{1,8,9},
 Johanna Mäenpää^{3,4,10}, Kristine Madsen⁵, Karen Stampe Petersson⁵, Mansoor Raza
 Mirza^{5,11}, Line Bjørge^{*,1,2}
- 9

¹Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of
 Bergen, Bergen, Norway

- 12 ²Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,
- 13 Norway
- ¹⁴ ³Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University
- 15 Hospital, Tampere, Finland
- ⁴Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Tampere,
- 17 Finland
- 18 ⁵Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU),
- 19 Copenhagen, Denmark
- 20 ⁶Department of Health Registry Research and Development, Norwegian Institute of
- 21 Public Health, Oslo, Norway
- ⁷Kinn Therapeutics AS, Bergen, Norway

- ²³ ⁸Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,
- 24 Norway
- ⁹Department of Internal Medicine, Hematology Section, Haukeland University Hospital,
- 26 Bergen, Norway
- ¹⁰Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- ¹¹Department of Oncology, Rigshospitalet, Copenhagen University Hospital,
- 29 Copenhagen, Denmark
- 30 *Corresponding author
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 41
- 42

43 **ABSTRACT**

Background: Clinical trials of immune checkpoint inhibitors in epithelial ovarian cancer 44 (EOC) have not shown clear survival benefit, 45 likely due to the complex 46 immunosuppressive mechanisms of the EOC tumor microenvironment. Still, certain patients experience long-term treatment benefit. However, we lack reliable biomarkers 47 for distinguishing dominant immunosuppressive mechanisms and for identifying patients 48 49 with EOC who are responsive to immunotherapy. The present high-dimensional singlecell study analyzed patients with relapsed EOC enrolled in arm A of the NSGO-OV-50 UMB1/ENGOT-OV30 trial, wherein the patients underwent combination oleclumab (anti-51 CD73) and durvalumab (anti-PD-L1) immunotherapy. The objective of the study was the 52 53 identification of blood-based immunophenotypic signatures conducive to the 54 development of improved strategies for patient selection, response monitoring, and 55 personalized targeting of immunosuppressive mechanisms.

56 **Methods:** A 40-marker suspension mass cytometry panel was utilized for 57 comprehensive phenotypic and functional characterization of longitudinally sampled 58 peripheral blood leukocytes from patients. Artificial neural network-based unsupervised 59 clustering and manual metacluster curation were used to identify leukocyte subsets for 60 differential discovery and correlation analyses.

Results: At baseline, short-term and long-term survivors differed with regard to the relative abundances of total peripheral blood mononuclear cells (PBMCs). We observed a significant increase in CD14⁺CD16⁻ myeloid cells during treatment, initially driven by classical monocyte proliferation and subsequently driven by the expansion of monocytic myeloid-derived suppressor cells (M-MDSCs). This M-MDSC expansion occurred only in

66 patients with shorter progression-free survival, who also showed a continuous decrease 67 in central memory T-cell abundances after baseline. Throughout treatment, we observed 68 upregulation of PD-L1 expression on most T-cell subsets in all patients. Higher 69 expression of CD73 and IDO1 on select leukocyte subsets at baseline was significantly 70 positively correlated with longer progression-free survival.

71 **Conclusions:** Our study delineates the phenotypic and functional alterations in 72 peripheral blood leukocytes occurring during combination oleclumab/durvalumab immunotherapy in patients with relapsed EOC. We propose a set of biomarkers with 73 potential for treatment personalization and response monitoring: relative abundances of 74 PBMCs at baseline, relative abundances of M-MDSCs and central memory T cells 75 76 during treatment; PD-L1 expression levels over time; and baseline expression of CD73 and IDO1 on specific leukocyte subsets. However, validation of these biomarkers 77 78 through larger-scale studies is required.

79

80 KEY MESSAGES

81 WHAT IS ALREADY KNOWN ON THIS TOPIC

Despite promising preclinical results and moderate efficacy in lung cancer, combination anti-CD73/anti-PD-L1 immunotherapy in relapsed epithelial ovarian cancer (EOC) has shown only modest response rates, consistent with other EOC immunotherapy trials. Durable clinical benefit remains rare, and there are currently no biomarkers available for the effective selection of EOC patients for personalized immunotherapy and for the characterization of sustained responses.

88 WHAT THIS STUDY ADDS

This study demonstrates that, at baseline of combination anti-CD73/anti-PD-L1 89 treatment, EOC patients with higher relative abundances of peripheral blood 90 91 mononuclear cells (PBMCs) and elevated expression of CD73 and IDO1 on certain 92 PBMC subsets may experience greater overall survival and progression-free survival benefit, respectively. Additionally, patients with faster disease progression exhibited a 93 94 shift in CD14⁺CD16⁻ myeloid cells towards a more immunosuppressive phenotype and had lower abundances of central memory T cells over time compared to patients with 95 slower progression, while PD-L1 expression increased significantly over time on T cells 96 of all patients, regardless of the rate of disease progression. 97

98

99 HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

While further clinical validation is required, we propose blood-based biomarkers for predicting and monitoring responses to immunotherapy in EOC, aiming to guide future research on immunotherapy resistance mechanisms and treatment personalization, with a focus on specific peripheral leukocyte subsets.

104

105 KEYWORDS

Humans; Epithelial ovarian cancer; Immunotherapy; Immune checkpoint inhibitor;
durvalumab; oleclumab; Mass Cytometry; Myeloid-derived suppressor cells; Leukocytes,
Mononuclear; Biomarkers

109 INTRODUCTION

110 Epithelial ovarian cancer (EOC) is predominantly diagnosed at an advanced stage. For 111 the past few decades, surgical cytoreduction followed by carboplatin-paclitaxel 112 chemotherapy has been the default approach to treating EOC [1]. Recently, the clinical 113 implementation of poly(ADP-ribose) polymerase inhibitors (PARPi's) and the anti-114 angiogenesis agent bevacizumab as maintenance therapy has significantly improved 115 survival [2]. However, despite most patients initially responding to primary treatment, 116 70%-80% of the responders eventually experience relapse [3]. Although multiple 117 therapeutics are used to treat recurrent disease, the treatment intent shifts from curative 118 to palliative. Drug resistance and the dearth of effective post-relapse treatment options 119 have resulted in the long-term survival rates remaining low [4] and highlighted the need for novel treatment modalities. 120

121

122 Immunotherapy, particularly the clinical implementation of immune checkpoint inhibitors 123 (ICIs), has improved the outcomes of several cancers by disrupting tumor immune 124 evasion mechanisms, mainly the induction of T-cell exhaustion [5]. Seminal studies by 125 Zhang et al. [6] and Curiel et al. [7], correlating treatment response and survival with the 126 presence, position, and phenotypes of tumor-infiltrating lymphocytes in EOC, have 127 indicated rationale for applying immunotherapy in EOC as well. Although numerous trials on immunotherapeutic regimens in EOC have been conducted, including studies 128 129 incorporating patient pre-selection strategies based on predictive biomarkers, such as 130 PD-L1 [8], none have shown sufficient efficacy to be considered clinically viable [9]. 131 Immunotherapy has failed to achieve potency in EOC on account of multiple

immunoinhibitory mechanisms simultaneously active in its tumor microenvironment (TME). This facilitates a high degree of immunosuppression, unsurmountable by immunotherapeutics delivered either as a monotherapy or in combination with chemotherapeutics [10]. In preclinical studies on EOC, combination immunotherapy regimens have resulted in notable increases in antitumor efficacy over single-agent immunotherapeutics, predominantly by inhibition of PD-1/PD-L1 interaction alongside simultaneous activation of an immunostimulatory receptor on T cells [11].

139

140 Building off of promising preclinical results of combination immunotherapies in murine 141 models of solid cancers, which had shown significant synergistic effects in terms of 142 tumor reduction and survival improvement, as well as elevated abundance and anti-143 tumor activity of CD8⁺ T cells, compared to the corresponding monotherapies [12-14], 144 the non-randomized phase II trial NSGO-OV-UMB1/ENGOT-OV30 was designed as a 145 three-arm umbrella trial for testing the clinical efficacy of several novel combinations of 146 immunotherapeutics in patients with relapsed EOC [15]. The treatment in arm A 147 comprised oleclumab and durvalumab - human monoclonal IgG1 antibodies that target 148 and inhibit CD73 and PD-L1, respectively. CD73, an adenosine-generating extracellular 149 enzyme present on most normal tissues [16], is overexpressed in most cancers [17] and 150 associated with poor prognosis in EOC [18]. Binding of adenosine to A2A receptors on 151 antigen-activated T cells results in activation blockage and exhaustion [19]. Accordingly, 152 inhibition of the CD73/A2A receptor axis is considered an effective means of re-153 invigorating anti-tumor immunity [20]. Furthermore, simultaneous inhibition of CD73 and the PD-1/PD-L1 interaction in preclinical in vitro and in vivo human cell line models was 154 shown to have a synergistic anti-tumor effect compared to the individual inhibition of 155

either [21]. Based on these results, the oleclumab/durvalumab combination was approved for testing in a phase II clinical trial setting [15]. While it demonstrated only marginal clinical efficacy in a relapsed EOC cohort, a number of patients exhibited prolonged survival.

160

This translational study presents the results of the high-dimensional single-cell 161 suspension cytometry by time-of-flight (CyTOF) analysis of blood samples collected from 162 163 trial cohort A prior to treatment and at regular intervals during treatment. The aim was 164 the elucidation of clinically actionable phenotypic signatures of the response of relapsed EOC to oleclumab/durvalumab immunotherapy. We identified potential leukocyte-based 165 166 predictive, prognostic, and response biomarkers for the purposes of improved patient 167 selection, preemptive detection of cancer progression, and portrayal of *in vivo* drug 168 activity, respectively.

169

170 **METHODS**

171 **Patient cohort and samples**

In the international NSGO-OV-UMB1/ENGOT-OV-30 umbrella trial, 25 immunotherapy-172 naïve patients with relapsed EOC who had CD73-positive archival tumor samples were 173 174 included in arm A and intravenously administered 3000 mg oleclumab and 1500 mg durvalumab every two and four weeks, respectively (figure 1A). The primary endpoint 175 176 was response evaluation (disease control rate) at the 16-week timepoint. Peripheral 177 blood samples for single-cell suspension CyTOF were collected in 10 mL EDTA Vacutainer tubes (Becton Dickinson, REF 367525) at baseline (pre-treatment), at 178 179 minimum every two 28-day cycles, and at end of trial or at disease progression. Within

one hour of collection, samples were processed using BD Phosflow Lyse/Fix buffer
(Becton Dickinson, REF 558049) and frozen at -80°C (figure 1B,C) (protocol described
in the online supplemental appendix). Samples were stored in the biobank of Haukeland
University Hospital, Bergen, Norway.

184

185 Mass cytometry panel development

186 A 40-marker antibody panel (online supplemental table S1) encompassing the entire human peripheral blood leukocyte repertoire was designed and developed in-house for 187 188 in-depth single-cell analysis of the leukocvte samples. As the aim of oleclumab/durvalumab immunotherapy was the reinvigoration of T cells from an 189 190 exhausted state, a central objective of the panel was ascertainment of information about 191 T-cell states before and during treatment. Given that myeloid cells in the peripheral 192 blood have been observed to significantly influence the outcome of immunotherapy of 193 solid cancers [22], as well as have a crucial influence on treatment outcome upon settlement into the TME of EOC [23], another objective of the panel was the 194 195 characterization of the myeloid cells in the samples.

For antibody clones not commercially available in a pre-metal-conjugated format, 100 µg of purified, carrier-protein-free antibody was conjugated in-house to cadmium- or lanthanide-loaded polymers using Maxpar MCP9 or X8 antibody labeling kits, respectively, according to the manufacturer's protocol (Standard BioTools).

200 Antibodies were titrated on leukocytes from whole blood collected from healthy female 201 donors and processed using the Lyse/Fix buffer. Titration of lineage and cell state

markers was performed on unstimulated leukocytes, and peripheral blood mononuclear 202 203 cells (PBMCs) stimulated in vitro by interleukin-2 (IL-2) (Sigma, Cat.No. I2644) and 204 phytohemagglutinin-P (PHA-P) (Sigma, Cat.No. 61764), respectively, according to the 205 protocol in the online supplemental appendix. To ensure consistency, identical sample 206 processing and staining protocols were maintained for the titration samples and clinical samples. The optimal concentration of Cell-ID Intercalator-Ir (Standard BioTools, Cat.No. 207 201192B) for the identification of nucleated cells was determined to be 250 nM by 208 209 titration. The panel was validated for use on the CyTOF XT mass cytometer (Standard 210 BioTools).

211

212 Sample staining and data acquisition

213 To facilitate uniform staining, batches containing up to 20 samples were designed, wherein a unique palladium-based tag was assigned to each sample. For batch effect 214 correction, each barcoded batch contained two different anchor samples consisting of 215 216 Lyse/Fix-treated healthy donor leukocytes, one of which had an admixture of PHA-P/IL-217 2-treated healthy donor PBMCs to enable batch correction of activation/exhaustion 218 markers. Frozen fixed leukocyte samples were thawed and treated with 0.25 mg/mL 219 DNAse I (Sigma, Cat.No. DN25) dissolved in Dulbecco's phosphate-buffered saline containing Ca²⁺ and Mg²⁺ (Sigma, Cat.No. D8662) (henceforth referred to as "DNAse"). 220 Cells were counted, and a maximum of 3.5×10^6 cells from each sample were tagged 221 222 using a palladium-based barcoding method according to the manufacturer's protocol 223 (Standard BioTools, Cat.No. 201060). Barcoding reagents were washed away, and all 224 cells within a batch were pooled, counted, and frozen at -80°C.

To maintain consistency in the composition of staining antibody mixes across sample batches, two mixes of antibodies, targeting either surface or intracellular markers, were pre-made in quantities large enough to stain the full set of samples, aliquoted, and stored at -80°C. Comparative testing of frozen versus freshly-made antibody mixes on Lyse/Fix-treated healthy donor leukocytes demonstrated that freezing did not affect the effectiveness or specificity of the panel antibodies.

231 For staining, barcoded sample mixes were thawed and counted. Cells were then incubated in MaxPar Cell Staining Buffer (CSB) (Standard BioTools, Cat.No. 201068) 232 containing human FcR Blocking Reagent (Miltenyi Biotec, Cat.No. 130-059-901), and 233 234 heparin (Ratiopharm, Reg.No. 5394.00.00) to prevent non-specific antibody binding. 235 Aliquots of the antibody mix for staining cell surface proteins were thawed and added to the cells at 3×10⁶ cells per 100 µL of staining volume. After incubating for 45 minutes at 236 237 room temperature (RT), superfluous antibody was washed away with MaxPar CSB, then 238 with MaxPar phosphate-buffered saline (PBS) (Standard BioTools, Cat.No. 201058), 239 after which cells were permeabilized by a 10-minute incubation in pure methanol 240 (Sigma, Cat.No. 32213) at -20°C. The methanol was washed away with MaxPar PBS, 241 followed by MaxPar CSB. Aliquots of the antibody mix for targeting intracellular proteins 242 were thawed and applied to the permeabilized cells for 30 minutes at RT, at a concentration of 3×10⁶ cells per 100 µL of staining volume. For DNA staining, washed 243 244 cells were incubated with iridium intercalator diluted in MaxPar PBS containing 4% V/V 245 formaldehyde for 20 min at RT. The cells were washed, resuspended in a 10% V/V 246 solution of dimethyl-sulfoxide (Sigma, Cat.No. W387520) in fetal bovine serum (Sigma, 247 Cat.No. F7524) and frozen at -80°C.

For data acquisition, fully stained cells were thawed, washed using MaxPar CSB, and 248 249 incubated in DNAse. Cells were then washed and pelleted in MaxPar Cell Acquisition 250 Solution (Standard BioTools, Cat.No 201240), kept on ice until data acquisition, and 251 acquired in MaxPar Cell Acquisition Solution Plus (Standard BioTools, Cat.No. 201244). 252 High-dimensional data from three barcoded batches was acquired on a CyTOF XT mass cytometer at ~400 events per second, with EQ Six-Element Calibration Beads (Standard 253 254 BioTools, Cat.No. 201245) present in the suspension at a 1:10 dilution (detailed 255 barcoding and staining methodologies provided in the online supplemental appendix).

256

257 Data pre-processing

258 Bead-based longitudinal signal intensity normalization was done automatically by the 259 CyTOF XT software upon data acquisition. Events were de-barcoded using the MATLAB 260 Compiler Runtime (R2013a(8.1)) implementation of The Single Cell Debarcoder by Zunder et al. [24]. De-barcoded events were uploaded to Cytobank (Beckman Coulter 261 Inc.), where irregular events were removed by manual gating (online supplemental figure 262 S1). The resulting single-cell events were batch corrected with the R-based GUI 263 264 implementation of CytofBatchAdjust by Schuyler et al. (v0.0.0.9001) [25], using the 265 composite anchor sample of each batch. Batch correction effectiveness was assessed 266 by analyzing the corrected data of the alternate anchor sample.

267

268 Clustering and differential analyses

269 Unsupervised clustering, dimensionality reduction, manually curated metaclustering, and 270 differential analyses were performed using the "flowSOM" [26], "umap" [27], 271 "CATALYST" [28], and "diffcyt" [29] R packages, respectively.

272 Total leukocyte data from all patient samples was first clustered into a 64-cluster (8x8) 273 self-organizing map (SOM) and manually metaclustered into granulocyte, PBMC, and 274 debris subsets based on the expression of 13 markers (figure 2A). The assignment of 275 cell identity was rigorously quality checked using biaxial plots, heatmaps, UMAPs, and hierarchical clustering of clusters. The PBMC subset was further sub-clustered into a 276 256-cluster (16×16) SOM and manually grouped into 24 subsets corresponding to 277 widely established PBMC types using 22 markers (figure 2B). Subset assignment was 278 279 validated in the same manner as that for total leukocytes.

280

281 Statistical analyses

Differential subset abundance and cell state marker expression between clinical sample groups, stratified by length of survival, duration of progression-free survival (PFS), or sampling timepoint, were analyzed using the edgeR and limma functions of the diffcyt R package, respectively. Multiple hypothesis testing correction was conducted using the Benjamini-Hochberg method, giving adjusted p-values (p_{adj}).

To identify potential predictive biomarkers among baseline leukocyte characteristics, the relationships between PFS duration, and either relative cell subset abundances or state marker expression medians for each cell subset were analyzed using GraphPad Prism (v10.2.0, GraphPad Software). Given that patients in the short-term survivor group had

291 died prior to the first tumor evaluation timepoint, this analysis was restricted to the seven 292 patients in the long-term survivor group. According to the results of Shapiro-Wilk 293 normality testing (alpha=0.05), either a Pearson or Spearman correlation test was performed for each marker-subset combination (dataset) alongside simple linear 294 295 regression to assess the relationship between PFS duration and relative abundances or 296 expression medians. The p-values in the correlation analyses were not corrected for 297 multiple hypothesis testing due to the small size of datasets (n=7) and the discovery-298 driven nature of this study. To maintain robustness, we considered significant correlations with an absolute correlation coefficient of at least 0.5 and an R-squared 299 300 value of at least 0.75 as meaningful.

301

302 **RESULTS**

303 Study cohort demographics

In this retrospective translational study, we analyzed total leukocytes longitudinally 304 305 sampled from patients with relapsed EOC undergoing combination 306 oleclumab/durvalumab immunotherapy (figure 1A) with the aim of identifying predictive, 307 prognostic, and response biomarkers for the administered treatment. Out of the 25-308 patient trial cohort, 16 patients were not eligible for this study due to samples either 309 missing or being of inadequate quality (figure 1B). Therefore, the data in this study 310 stems from 36 leukocyte samples of nine patients (figure 1C). Nonetheless, our study cohort is highly representative of the clinical trial cohort [15], as the patient age range 311 312 and distributions of FIGO stage, ECOG status, and clinical response are similar (table

- 1). In contrast to the patients in the clinical trial, the majority of the patients included in
- this study had undergone more extensive treatment prior to inclusion.

332 **Table 1** Characteristics of the included patients.

Age, years (%)Median (range)66 (47-74) $40-49$ 1 (11.1) $50-59$ 1 (11.1) $60-69$ 3 (33.3) ≥ 70 4 (44.4)FIGO stage at initial diagnosis (%)I1 (11.1)II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)1 (11.1)03 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3) ≥ 3 6 (66.7)Treatment cycles received* (%)Median (range)6 (1-15) ≤ 4 4 (44.4)>45 (55.6)Time to progression (weeks) (%) ≤ 116 3 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%) CR CR 0 (0.0)PR1 (11.1)N/A**2 (22.2)	Characteristic	No. of patients (n=9)
$40-49$ 1 (11.1) $50-59$ 1 (11.1) $60-69$ 3 (33.3) ≥ 70 4 (44.4)FIGO stage at initial diagnosis (%)I1 (11.1)II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3) ≥ 3 6 (66.7)Prior treatment lines (%)223 (33.3) ≥ 3 6 (56.6)Time to cycles received* (%)Median (range)6 (1-15) ≤ 4 4 (44.4) >4 5 (55.6)Time to progression (weeks) (%) ≤ 16 3 (33.3) > 16 4 (44.4) N/A^{**} 2 (22.2)Best clinical response (%)CRCR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	Age, years (%)	
50-59 1 (11.1) 60-69 3 (33.3) ≥70 4 (44.4) FIGO stage at initial diagnosis (%) 1 I 1 (11.1) II 0 (0.0) III 3 (33.3) IV-A 4 (44.4) IV-B 1 (11.1) ECOG PS at baseline (%) 0 0 3 (33.3) 1 6 (66.7) Prior treatment lines (%) 2 2 3 (33.3) ≥3 6 (66.7) Treatment cycles received* (%) Median (range) 6 (1-15) ≤4 4 (44.4) >4 5 (55.6) Time to progression (weeks) (%) 1 ≤16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	Median (range)	66 (47-74)
60-69 3 (33.3) ≥70 4 (44.4) FIGO stage at initial diagnosis (%) 1 I 1 (11.1) II 0 (0.0) III 3 (33.3) IV-A 4 (44.4) IV-B 1 (11.1) ECOG PS at baseline (%) 0 0 3 (33.3) 1 6 (66.7) Prior treatment lines (%) 2 2 3 (33.3) ≥3 6 (66.7) Treatment cycles received* (%) 1 Median (range) 6 (1-15) ≤4 4 (44.4) >4 5 (55.6) Time to progression (weeks) (%) 1 ≤16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	40-49	1 (11.1)
≥704 (44.4)FIGO stage at initial diagnosis (%)I1 (11.1)II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CRCR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	50-59	1 (11.1)
FIGO stage at initial diagnosis (%)I1 (11.1)II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%) $$	60-69	3 (33.3)
I1 (11.1)II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	≥70	4 (44.4)
II0 (0.0)III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CRCR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	FIGO stage at initial diagnosis (%)	
III3 (33.3)IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%) 0 03 (33.3)16 (66.7)Prior treatment lines (%) 2 23 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	1	1 (11.1)
IV-A4 (44.4)IV-B1 (11.1)ECOG PS at baseline (%)003 (33.3)16 (66.7)Prior treatment lines (%)223 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	II	0 (0.0)
IV-B1 (11.1)ECOG PS at baseline (%) 0 03 (33.3)16 (66.7)Prior treatment lines (%) 2 23 (33.3) ≥ 3 6 (66.7)Treatment cycles received* (%) $Median (range)$ Median (range)6 (1-15) ≤ 4 4 (44.4)>45 (55.6)Time to progression (weeks) (%) ≤ 16 3 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%) CR CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	III	3 (33.3)
ECOG PS at baseline (%)03 (33.3)16 (66.7)Prior treatment lines (%) 2 23 (33.3) ≥ 3 6 (66.7)Treatment cycles received* (%) 6 (1-15) ≤ 4 4 (44.4)>45 (55.6)Time to progression (weeks) (%) ≤ 16 ≤ 16 3 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%) CR CR 0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	IV-A	4 (44.4)
03 (33.3)16 (66.7)Prior treatment lines (%) 2 23 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	IV-B	1 (11.1)
16 (66.7)Prior treatment lines (%)23 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	ECOG PS at baseline (%)	
Prior treatment lines (%) 3 (33.3) ≥3 6 (66.7) Treatment cycles received* (%) Median (range) Median (range) 6 (1-15) ≤4 4 (44.4) >4 5 (55.6) Time to progression (weeks) (%) ≤ ≤16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	0	3 (33.3)
23 (33.3)≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	1	6 (66.7)
≥36 (66.7)Treatment cycles received* (%)Median (range)6 (1-15)≤44 (44.4)>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	Prior treatment lines (%)	
Treatment cycles received* (%) Median (range) 6 (1-15) ≤ 4 4 (44.4) >4 5 (55.6) Time to progression (weeks) (%) \leq ≤ 16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) \subset CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	2	3 (33.3)
Median (range) 6 (1-15) ≤ 4 4 (44.4)>4 5 (55.6)Time to progression (weeks) (%) ≤ 16 3 (33.3)>16 4 (44.4)N/A** 2 (22.2)Best clinical response (%) CR CR 0 (0.0)PR 1 (11.1)SD 5 (55.6)PD 1 (11.1)	≥3	6 (66.7)
≤ 4 4 (44.4)>45 (55.6)Time to progression (weeks) (%) ≤ 16 3 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%)CRCR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	Treatment cycles received* (%)	
>45 (55.6)Time to progression (weeks) (%)≤163 (33.3)>164 (44.4)N/A**2 (22.2)Best clinical response (%) CR CR0 (0.0)PR1 (11.1)SD5 (55.6)PD1 (11.1)	Median (range)	6 (1-15)
Time to progression (weeks) (%) ≤ 16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	≤4	4 (44.4)
≤16 3 (33.3) >16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	>4	5 (55.6)
>16 4 (44.4) N/A** 2 (22.2) Best clinical response (%) CR CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	Time to progression (weeks) (%)	
N/A** 2 (22.2) Best clinical response (%) 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	≤16	3 (33.3)
Best clinical response (%) CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	>16	4 (44.4)
CR 0 (0.0) PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	N/A**	2 (22.2)
PR 1 (11.1) SD 5 (55.6) PD 1 (11.1)	Best clinical response (%)	
SD 5 (55.6) PD 1 (11.1)	CR	0 (0.0)
PD 1 (11.1)	PR	1 (11.1)
	SD	5 (55.6)
N/A** 2 (22.2)	PD	1 (11.1)
	N/A**	2 (22.2)

*One cycle corresponds to four weeks of treatment.

334 ** Patients passed away prior to the first post-baseline tumor evaluation.

335 FIGO - International Federation of Gynecology and Obstetrics

336 ECOG PS - Eastern Cooperative Oncology Group performance status

338 CyTOF analysis enabled in-depth characterization of patients' leukocyte profiles

339 We utilized single-cell suspension CyTOF for high-dimensional phenotypic profiling of patient leukocytes. Approximately 21 million total events were acquired from the 36 340 341 leukocyte samples. After quality controls, single-cell data of about 19 million leukocytes 342 remained for further analysis. After batch correction, unsupervised clustering using FlowSOM and manual metaclustering of the total leukocytes produced three leukocyte 343 344 subsets - granulocytes, PBMCs, and debris (figure 2A). To achieve the intended analytical depth, the same clustering and metaclustering procedures were applied in 345 higher resolution to the PBMCs, resulting in the clear delineation of 24 PBMC subsets 346 347 (figure 2B). The robustness of the PBMC (meta)clustering was confirmed by using the 348 UMAP dimensionality reduction algorithm on an aggregated dataset comprising 10,000 349 PBMCs from each of the 36 samples (figure 2C).

All PBMC subtypes, except for the rarest populations (plasmablasts, CD141⁺ myeloid 350 dendritic cells, and CD4⁺CD8⁺ T cells), were detected in all samples (figure 2D, online 351 352 supplemental table S2). Inspection of the complete dataset revealed that each patient's 353 leukocyte profile remained largely consistent over time, but inter-patient heterogeneity 354 was markedly more pronounced (figure 2D). Nevertheless, certain trends in 355 compositional changes of leukocyte profiles over time were observed, such as the 356 expansion of myeloid cells at the cost of overall T-cell proportions in nearly all patients. To determine the significance of these observations for biomarker discovery, we 357 358 performed differential analyses of leukocyte composition and cell state marker 359 expression.

360

361 Long-term survivors exhibit larger abundances of PBMCs at baseline

To identify clinically relevant predictive biomarkers, patients were first stratified into short-term survivors (\leq 16 weeks, n=2) and long-term survivors (>16 weeks, n=7). We observed that long-term survivors had, on average, significantly higher relative abundance of total PBMCs at baseline (p_{adj}=0.0279) (figure 3A,B). No significant differences were observed in the relative abundances of other cell subsets between the groups at baseline. As the short-term survivors provided only baseline samples, we could not compare other timepoints between the groups.

369

Oleclumab/durvalumab treatment was accompanied by significant CD14⁺CD16⁻ myeloid cell expansion

372 To ensure consistency and sufficient sample size for adequate statistical power when 373 analyzing longitudinal changes, we evaluated only the samples from long-term survivors 374 taken at baseline (n=7) and after two (n=7) and four treatment cycles (n=7). Compared to baseline, the average frequency of classical monocytes (CD14⁺CD16⁻HLA-DR^{+/hi}) in 375 376 the peripheral blood samples significantly increased (padi=0.0248) after two treatment 377 cycles and remained elevated even after four treatment cycles, although not significantly 378 (p_{adi}=0.299) (figure 3C, left panel). Although there were no significant differences in the relative abundances of monocytic myeloid-derived suppressor cells (M-MDSCs) 379 (CD14⁺CD16⁻HLA-DR^{-/lo}) over time when analyzed separately from classical monocytes 380 (figure 3C, middle panel), removing the division between classical monocytes and M-381 MDSCs based on HLA-DR expression (online supplemental figure S2) revealed a 382

significant expansion of CD14⁺CD16⁻ myeloid cells relative to baseline. This expansion was evident after two treatment cycles (p_{adj} =0.0165) and persisted even after four treatment cycles (p_{adj} =0.0231) (figure 3C, right panel). We visualized this progressive increase in abundance by using UMAP to generate density-colored projections of aggregate samples of PBMCs from each timepoint (figure 3D).

388

389 Myeloid MDSC expansion and central memory T-cell contraction are tied to 390 progression onset

391 All seven patients in the long-term survivor group experienced tumor progression and were subsequently categorized either as rapid progressors (n=3), who experienced 392 disease progression within the first 16 weeks (four cycles) of treatment, or slow 393 394 progressors (n=4), who had disease progression more than 16 weeks from the start of 395 treatment. Differential abundance analyses showed significant expansion of the M-MDSC subset after four treatment cycles in the rapid progressors ($p_{adi}=6.89\times10^{-8}$) (figure 396 397 3E, left panel), with no significant longitudinal changes in subset abundance occurring in 398 the slow progressors (figure 3E, right panel). Furthermore, among rapid progressors, we 399 observed a consistent decline, leading to a statistically significant contraction, of both $CD4^{+}$ (p_{adj}=0.0477) and $CD8^{+}$ (p_{adj}=0.0477) central memory ($CD27^{+}CD45RO^{+}CD45RA^{-}$) 400 401 T-cell (T_{CM}) subsets after four treatment cycles (figure 3F, two left panels). This trend 402 was not observed among the slow progressors (figure 3F, two right panels).

For five out of the seven long-term survivors, samples from before and after confirmationof progression were available. We noted a marked trend towards increased abundance

of M-MDSCs following progression (figure 3G); however, this did not reach statistical significance ($p_{adj}=0.0537$).

407

408 PD-L1 expression is upregulated on T cells during oleclumab/durvalumab 409 treatment

We subsequently performed differential analyses of cell state marker expression levels 410 411 to investigate inter-group differences and longitudinal changes in the activation, 412 exhaustion, or terminal differentiation of leukocytes, as well as in the activity of signaling 413 pathways potentially influenced by inhibition of adenosinergic signaling [30]. Differential analyses of state marker expression levels between treatment timepoints and baseline 414 415 in the long-term survivors revealed significant upregulation of PD-L1 expression across 416 nearly all CD4⁺ and CD8⁺ T-cell subsets (figure 4). After two treatment cycles, PD-L1 417 expression was significantly increased in all memory (CD45RO⁺) T-cell subsets and 418 across all CD4+ T-cell subsets, with the CD4⁺ memory T cells showing the highest 419 expression and largest increases (figure 4A - left panel; figure 4B). Following four 420 treatment cycles, PD-L1 expression was significantly elevated compared to baseline in 421 all T-cell subsets except the effector memory (CD27⁻CD45RO⁺CD45RA⁻) T-cell subsets 422 (figure 4A - right panel; figure 4B). Notably, the lowest PD-L1 expression among the Tcell subsets was observed in the naive (CD27⁺CD45RO⁻CD45RA⁺) T-cell subsets (figure 423 424 4B).

425 Comparisons of cell state marker expression between rapid and slow progressors, as 426 well as between pre- and post-progression samples, did not reveal any significant

427 differences. Interestingly, no significant changes or trends were observed in the 428 expression levels of markers associated with the adenosinergic signaling pathway 429 (CD39, CD73, p-CREB, and p-S6) (data not shown).

430

Baseline expression levels of CD73 and IDO1 positively correlate with the duration of progression-free survival

433 To assess the impact of baseline abundances and phenotypes of peripheral blood 434 leukocytes on PFS duration, we performed correlation analyses. No significant valid correlations were found between baseline subset abundances and PFS duration (figure 435 5A) (online supplemental table S3). However, analyses of cell state marker expression 436 revealed a strong positive correlation between baseline CD73 expression and PFS 437 438 duration for most of the subsets comprising the patients' peripheral blood leukocyte 439 repertoire (figure 5B). This correlation met the predefined robustness criteria in approximately one third of leukocyte subsets, predominantly encompassing the majority 440 of the T-cell repertoire. Similarly, a strongly positive correlation with PFS duration was 441 442 also observed for baseline IDO1 expression in a number of leukocyte subsets, although 443 this correlation was significant in fewer subsets than observed for CD73 expression 444 (figure 5C).

445

446 **DISCUSSION**

In this study, we report the findings from a high-dimensional single-cell analysis of blood
samples from patients with relapsed EOC undergoing combination

medRxiv preprint doi: https://doi.org/10.1101/2024.10.02.24314755; this version posted October 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

oleclumab/durvalumab immunotherapy. To the best of our knowledge, this is the first 449 study to employ single-cell CyTOF to assess blood-based biomarkers in patients with 450 451 ovarian cancer undergoing immunotherapy. Through differential and correlative analyses of the abundances and phenotypes of peripheral blood leukocytes, we identified 452 453 phenotypic signatures potentially indicative of disease progression and treatment efficacy. We show that patients with relapsed EOC who present with lower proportions of 454 455 PBMCs in their peripheral blood leukocyte pool may derive inferior survival benefit from 456 combined oleclumab/durvalumab treatment than patients with higher proportions of 457 PBMCs. During treatment, we saw an increase in the relative abundance of circulating CD14⁺CD16⁻ myeloid cells in the total patient cohort, along with a decrease in T_{CM} cell 458 459 proportions specific to rapidly progressing patients. We also observed a strong trend towards an increased relative abundance of circulating M-MDSCs at progression. 460 461 Furthermore, we noted a significant increase in PD-L1 expression on circulating T cells during treatment. Finally, we demonstrate that PFS duration was positively correlated 462 463 with pre-treatment expression levels of CD73 and IDO1 on several circulating leukocyte 464 subsets.

In our study cohort, long-term survivors exhibited significantly higher proportions of total PBMCs at baseline compared to short-term survivors, which aligns with studies on PD-1/PD-L1 checkpoint blockade in lung cancer and melanoma demonstrating significant association between lower baseline neutrophil-to-lymphocyte ratios and improved progression-free and overall survival [31,32]. Correspondingly, patient P4, who exhibited the highest relative abundance of lymphocytes at baseline among all patients (figure 2D), was the sole responder in the trial and demonstrated the longest survival. This data

472 suggests that EOC patients possessing an immune system more effectively primed for473 adaptive response may derive more consistent benefit from immunotherapy.

474 We observed a significant expansion of the CD14⁺CD16⁻ myeloid cell compartment over 475 the course of the first four treatment cycles. This expansion was initially driven by an increased abundance of HLA-DR^{+/hi} classical monocytes in the total cohort, and further 476 sustained by an elevated frequency of HLA-DR^{-/lo} M-MDSCs in rapid progressors. This 477 478 indicates a shift of the CD14⁺CD16⁻ myeloid compartment towards a more immunosuppressive phenotype. Therefore, a sudden increase in the proportions of M-479 MDSCs in the peripheral blood of EOC patients treated with anti-CD73/PD-L1 480 481 immunotherapy may serve as a potential biomarker of disease progression. Accordingly, 482 higher HLA-DR expression on cells within the CD14⁺CD16⁻ myeloid cell compartment 483 has been positively associated with improved response to oleclumab [21] and immunotherapy targeting the PD-1/PD-L1 pathway [33]. 484 Furthermore, cancer 485 immunotherapy trials have consistently demonstrated that elevated MDSC abundance is 486 associated with worse outcome in EOC [34], and various other cancers [35-37]. Growth 487 factors and proinflammatory cytokines produced by cancer cells chronically stimulate 488 myeloid progenitors, driving their differentiation towards M-MDSCs. Similarly, tumor-489 derived factors can induce the reprogramming of classical monocytes already present in 490 peripheral blood towards M-MDSCs [38]. This expanded population of CD14⁺CD16⁻ 491 myeloid cells, likely representing precursors to tumor-associated macrophages, can be 492 recruited to ovarian tumors, resulting in enhanced immunosuppression [34]. We 493 hypothesize that EOC's concurrent utilization of a multitude of immunosuppressive 494 mechanisms allows it to adapt and effectively resist targeted immunotherapy through

enhancement of immunosuppression mechanisms not currently affected by treatment.
Such adaptation may be addressed by modifications or additions to the existing
therapeutic approach. In line with this notion, MDSC-targeting agents have been
preclinically and clinically evaluated in EOC with promising beneficial effect, also in
combination with other immunotherapeutic approaches [34,39].

500 Our analysis showed a significant decline in the frequencies of T_{CM} cells in the 501 peripheral blood of rapid progressors. Such a decline may have occurred as a consequence of the evolving immunosuppression in the underlying cancer. This 502 hypothesis is supported by the observation that the T_{CM}-cell decline coincides with a 503 504 substantial increase in peripheral M-MDSCs in these patients. T_{CM}-cell homeostasis may 505 have been disrupted by the collective inhibition of the activation and differentiation of 506 effector T cells into T_{CM} cells, and the inhibition of the reactivation and proliferation of tumor-proximal T_{CM} cells through an adaptive increase in adenosine generation. This 507 508 effect may have been mediated by upregulation or induction of CD39/CD73 expression 509 on tumor-recruited MDSCs [40], creating what is known as a "purinergic halo" [41]. The 510 role of adenosine in driving the contraction of the T_{CM} subset is further supported the 511 study of Mastelic-Gavillet et al., which showed that T_{CM} cells are especially vulnerable to 512 adenosine-mediated dysfunction due to their high expression of the A2A receptor [30].

A novel observation of this study was the significant increase of PD-L1 on circulating T cells over time during administration of an anti-PD-L1 ICI. Research on other solid cancers has identified intratumoral PD-L1⁺CD8⁺ T cells as drivers of T-cell exhaustion via the PD-L1/PD-1 axis, and as promoters of M2 macrophage polarization [42,43]. Given that PD-L1 upregulation on T cells occurs following activation, we postulate that

the observed longitudinal upregulation of PD-L1 on circulating T cells in patients with EOC receiving oleclumab/durvalumab is a consequence of rapidly induced and progressively mutual exhaustion of activated T-cells.

Interestingly, we did not observe any significant longitudinal changes or inter-group differences in the expression of markers associated with adenosinergic signaling (CD39, CD73, p-S6, and p-CREB). This contradicts previous findings that documented oleclumab-induced inhibition and internalization of CD73 on CD4⁺ and CD8⁺ T cells [44]. The stability of adenosinergic signaling observed in our study may be attributable to compensatory upregulation of CD73 expression, which possibly counteracted the expected oleclumab-mediated internalization.

528 Our study demonstrates a significant positive correlation between baseline CD73 529 expression across various leukocyte subsets and PFS duration. This contradicts the prevailing view that CD73 expression in cancer generally correlates with poorer 530 treatment outcome [45]. A limited number of studies have investigated CD73 expression 531 532 in EOC [18,46], and ours is the first to link baseline CD73 expression with outcome in 533 CD73-targeting cancer therapy. Although the positive correlation between baseline 534 CD73 expression and PFS duration was observed for a range of leukocyte subsets. 535 nearly all T-cell subsets are present in this set and represent a majority of the significant 536 results. Thus, elevated baseline CD73 expression on peripheral blood T cells may serve as a predictive marker of longer PFS in patients with EOC set to undergo anti-CD73 537 immunotherapy. We hypothesize that patients with higher baseline CD73 expression 538 539 may have had tumors more heavily dependent on adenosinergic signaling for immune evasion, potentially enhancing the effectiveness of anti-CD73 treatment. Nonetheless, 540

this advantage appears to be temporary, as all patients ultimately experienced progression. This development may be attributed to the inherent immunosuppressive adaptability of EOC, as evident by the observed expansion of M-MDSCs and upregulation of PD-L1 in T cells.

545 In addition to the observed positive correlation between CD73 and longer PFS, our 546 observation of a positive correlation between baseline IDO1 expression and longer PFS 547 during EOC immunotherapy is in alignment with previous reports [47,48]. Although IDO1 is generally viewed as a contributor to immunosuppression, our findings may be 548 explained by its role in upregulating PD-L1 through the activation of the aryl hydrocarbon 549 550 receptor by IDO1-generated tryptophan catabolites, as observed in solid tumors [49] and 551 murine models of EOC [50]. Consequently, higher IDO1 expression in specific cell subsets could lead to increased PD-L1 expression on the same cells, potentially 552 553 enhancing their susceptibility to durvalumab. Indeed, consistent with the study by 554 Fujiwara et al. [47], our data also demonstrated a positive correlation between IDO1 and 555 PD-L1 expression in leukocytes (online supplemental table S4). This correlation was significant and robust in subsets that showed the strongest associations between PD-L1 556 557 expression and PFS duration, namely, classical monocytes, M-MDSCs, and CD141⁺ 558 myeloid dendritic cells. Therefore, IDO1 expression in the peripheral blood myeloid 559 compartment may serve as a potential biomarker for the efficacy of EOC immunotherapy 560 targeting PD-L1. Despite strong correlation coefficients and significant p-values, the 561 validity of correlations between PD-L1 and PFS duration was limited by a low goodness-562 of-fit parameter, likely due to the small sample size. Therefore, a larger study is needed

to more definitively establish baseline PD-L1 expression in peripheral blood leukocytes
as a predictive biomarker for EOC immunotherapy utilizing anti-PD-L1 ICIs.

This study examined sequentially sampled peripheral blood. An advantage of using 565 566 blood samples, as opposed to tumor tissue biopsies, is that the information provided is 567 not limited to a specific anatomical location. This is particularly valuable in cases of 568 metastatic disease and offers a more comprehensive view of the patient's overall 569 condition. Additionally, blood sampling is more flexible, clinically accessible, costeffective, less invasive, and avoids the need for radiological imaging or surgical 570 procedures for sample acquisition. However, the implementation of our 40-marker panel 571 in the clinical setting is constrained by the high costs and complexity of the CyTOF 572 573 methodology. Therefore, a more focused set of markers or leukocyte subsets, as 574 suggested in this study, could represent a biomarker panel analyzable via methods 575 already utilized in routine clinical diagnostics, such as flow cytometry or ELISA.

Overall, the small number of patient samples in this study affects the statistical power 576 577 and limits the generalizability of the results. However, the diversity within the patient 578 population - encompassing a wide range of ages, disease stages, and prior treatments -579 adds to the robustness and relevance of our observations for a broader spectrum of 580 patients with relapsed EOC undergoing immunotherapy. Furthermore, the use of single-581 cell suspension CyTOF allowed us to generate extensive data from the limited sample 582 set. Coupled with high-dimensional unsupervised clustering algorithms, this approach provided numerous insights and perspectives, strengthening the conclusions of the 583 study. 584

Another limitation of this study is the absence of control arms comprising patients 585 586 treated with either oleclumab or durvalumab alone [15]. Such control groups would have provided data integral for the conclusive attribution of the observed differences in 587 leukocyte abundances and states to the effects of a certain immunotherapeutic. In 588 589 addition, patients had undergone multiple rounds of cancer therapy prior to inclusion, which may have exerted developmental pressure on the tumors and potentially 590 591 influenced response to oleclumab/durvalumab treatment. Although an expanded trial 592 including single-agent arms and newly diagnosed EOC patients would help clarify the individual contribution of each compound to treatment outcome, the limited clinical 593 594 activity of the oleclumab/durvalumab combination in the NSGO-OV-UMB1 trial [15] 595 makes it difficult and ethically questionable to initiate such a randomized phase II or III 596 trial.

In conclusion, our findings offer comprehensive insights into the effects of combination oleclumab/durvalumab immunotherapy on the peripheral blood leukocytes of relapsed EOC patients and elucidate potential immunosuppressive mechanisms employed by EOC to counteract the effects of immunotherapy. We propose blood-based biomarkers for better patient selection and non-invasive monitoring of disease progression; however, validation in larger patient cohorts is necessary.

603

604 **DECLARATIONS**

605 Author affiliations

- ⁶⁰⁶ ¹Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of
- 607 Bergen, Bergen, Norway
- ⁶⁰⁸ ²Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,
- 609 Norway
- ³Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University
- 611 Hospital, Tampere, Finland
- ⁴Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Tampere,
- 613 Finland
- ⁵Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU),
- 615 Copenhagen, Denmark
- ⁶Department of Health Registry Research and Development, Norwegian Institute of
- 617 Public Health, Oslo, Norway
- 618 ⁽Kinn Therapeutics AS, Bergen, Norway
- ⁶¹⁹ ⁸Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,
- 620 Norway
- ⁹Department of Internal Medicine, Hematology Section, Haukeland University Hospital,
- 622 Bergen, Norway
- ¹⁰Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 624 ¹¹Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 625 Copenhagen, Denmark

626

627 **Acknowledgements** We thank the patients for their consent and participation in 628 the study. We thank Brith Bergum and Jørn Skavland at the Flow Cytometry Core

Facility of the University of Bergen for providing support for our mass cytometry work.
We acknowledge BioRender.com as the platform used to create the figures in this
manuscript.

632

Authors' Contributions Study conceptualization and design: LT, MRM, LB. Clinical
sample collection: AA, JM, KM, KSP, MRM, LB. Clinical database administration: RdPC,
KM, KSP. Data generation: LT, CEW. Data analysis and statistics: LT. Data interpretation:
LT, KK, LCVT, EMC, LB. Manuscript writing and editing: LT, KK, LCVT, LB. Manuscript
review: All authors. Project administration: LT, KM, KSP, MRM, LB. Funding acquisition:
MRM, LB. Guarantors: MRM, LB.

639

Funding This work was supported by grants from the Western Norway Regional Health Authority (Project No. 28543) and the Research Council of Norway through its Centres of Excellence funding scheme (Project No. 223250). AstraZeneca provided a grant to partially fund the trial and the investigational medicinal products (oleclumab and durvalumab). The funding sources were not involved in the study design, the collection of data, or the analysis and interpretation of data.

646

Competing interests 647 AA has participated on the advisory boards of GlaxoSmithKline and Merck Sharp and Dohme; RdPC is employed by and is a 648 shareholder of Y-mAbs Pharmaceuticals; LCVT has received personal fees for lectures 649 650 from Bayer and AstraZeneca, personal fee payments from Eisai for participating on an

expert board, and has received a grant related to a clinical trial from AstraZeneca; CEW 651 652 has received financial support for conference attendance and travel expenses from 653 Beckman Coulter Inc.; EMC is a shareholder of KinN Therapeutics AS; JM has received a honorarium for a lecture from Eisai: KM has received speakers' honoraria and 654 655 received compensation for travel expenses from GlaxoSmithKline and AstraZeneca, has participated in a trial-specific safety review committee for Kancera AB, and is a deputy 656 657 medical director for NSGO-CTU; MRM has received an institutional study grant and investigational medicinal product from AstraZeneca (no personal grants were received); 658 LB has received honoraria for lectures from GlaxoSmithKline and Merck Sharp and 659 660 Dohme, has received a research grant from AstraZeneca for a researcher-initiated trial, 661 and has had leadership roles in Onkologisk Forum between 2018 and 2022 and in the NSGO and NSGO-CTU since 2021; LT, KK and KSP report no personal conflicts of 662 663 interest.

664

665 **Data availability statement** Data are available from the corresponding author 666 upon request.

667

668 **Ethics approval** The study protocol and use of patient material in this study was 669 approved by the regional ethical committees or institutional review boards of the 670 participating sites: The Scientific Ethics Committee for the Capital Region of Denmark 671 (VEK) (approval no. H-17025483), The Regional Committee for Medical Research 672 Ethics Western Norway (REK West) (approval no. 2018/580), and The Regional Ethics

673 Committee of the Expert Responsibility area of Tampere University Hospital (TAYS) 674 (approval no. R18078M). The study was conducted in accordance with the good clinical 675 practice guidelines and provisions of the Declaration of Helsinki, as well as according to 676 all local regulations.

677

678 **Patient consent** All patients provided written informed consent for use of the clinical 679 information and biological materials.

680

681 **Provenance and peer review** Not commissioned; externally peer reviewed.

682

683 **Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-684 reviewed. Any opinions or recommendations discussed are solely those of the author(s) 685 686 and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material. 687 688 BMJ does not warrant the accuracy and reliability of the translations (including but not 689 limited to local regulations, clinical guidelines, terminology, drug names and drug 690 dosages), and is not responsible for any error and/or omissions arising from translation 691 and adaptation or otherwise.

692

693 **Open access** This is an open access article distributed in accordance with the 694 Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, 695 redistribute, remix, transform and build upon this work for any purpose, provided the 696 original work is properly cited, appropriate credit is given, any changes made are 697 indicated. See: https://creativecommons.org/licenses/by/4.0/.

- 698
- 699 ORCID IDs
- 700 Luka Tandaric https://orcid.org/0009-0009-1431-2586
- 701 Annika Auranen https://orcid.org/0000-0002-9678-4684
- 702 Katrin Kleinmanns https://orcid.org/0000-0003-1402-8568
- 703 René DePont Christensen https://orcid.org/0009-0007-0919-236X
- 704 Liv Cecilie Vestrheim Thomsen <u>https://orcid.org/0000-0002-6787-8518</u>
- 705 Cara Ellen Wogsland <u>https://orcid.org/0000-0003-1797-7902</u>
- 706 Emmet McCormack https://orcid.org/0000-0002-7621-4625
- 707 Johanna Mäenpää https://orcid.org/0000-0003-0486-6912
- 708 Kristine Madsen <u>https://orcid.org/0009-0004-4552-1931</u>
- 709 Karen Stampe Petersson <u>https://orcid.org/0009-0008-9757-1913</u>
- 710 Mansoor Raza Mirza <u>https://orcid.org/0000-0002-8085-1010</u>
- 711 Line Bjørge <u>https://orcid.org/0000-0002-0240-2770</u>

712

713 **REFERENCES**

[1] L. Kuroki, S.R. Guntupalli. Treatment of epithelial ovarian cancer. BMJ 371 (2020)
 m3773. DOI:10.1136/bmj.m3773

A. Gadducci, S. Cosio. Randomized Clinical Trials and Real World Prospective
Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint
Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
Anticancer Res 41(10) (2021) 4673-4685. DOI:10.21873/anticanres.15281

[3] S.L. Cooke, J.D. Brenton. Evolution of platinum resistance in high-grade serous
ovarian cancer. Lancet Oncol 12(12) (2011) 1169-1174. DOI:10.1016/S14702045(11)70123-1

M. McMullen, A. Madariaga, S. Lheureux. New approaches for targeting platinumresistant ovarian cancer. Semin Cancer Biol 77 (2021) 167-181.
DOI:10.1016/j.semcancer.2020.08.013

[5] H.E. Marei, A. Hasan, G. Pozzoli, et al., Cancer immunotherapy with immune
checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for
reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23(1)
(2023) 64. DOI:10.1186/s12935-023-02902-0

[6] L. Zhang, J.R. Conejo-Garcia, D. Katsaros, et al., Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med 348(3) (2003) 203-213.
DOI:10.1056/NEJMoa020177

T.J. Curiel, G. Coukos, L. Zou, et al., Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med
10(9) (2004) 942-949. DOI:10.1038/nm1093

[8] A. Varga, S. Piha-Paul, P.A. Ott, et al., Pembrolizumab in patients with
programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE028. Gynecol Oncol 152(2) (2019) 243-250. DOI:10.1016/j.ygyno.2018.11.017

[9] B.A. Maiorano, M.F.P. Maiorano, D. Lorusso, et al., Ovarian Cancer in the Era of
Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers
(Basel) 13(17) (2021). DOI:10.3390/cancers13174438

[10] C. Yang, B.R. Xia, Z.C. Zhang, et al., Immunotherapy for Ovarian Cancer:
Adjuvant, Combination, and Neoadjuvant. Front Immunol 11 (2020) 577869.
DOI:10.3389/fimmu.2020.577869

[11] A. Martinez, J.P. Delord, M. Ayyoub, et al., Preclinical and Clinical
Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers (Basel) 12(7)
(2020). DOI:10.3390/cancers12071761

[12] B. Allard, S. Pommey, M.J. Smyth, et al., Targeting CD73 enhances the antitumor
activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19(20) (2013) 5626-5635.
DOI:10.1158/1078-0432.CCR-13-0545

[13] F. Polesso, A.D. Weinberg, A.E. Moran. Late-Stage Tumor Regression after PDL1 Blockade Plus a Concurrent OX40 Agonist. Cancer Immunol Res 7(2) (2019) 269281. DOI:10.1158/2326-6066.CIR-18-0222

[14] W.L. Redmond, S.N. Linch, M.J. Kasiewicz. Combined targeting of costimulatory
(OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of
driving robust antitumor immunity. Cancer Immunol Res 2(2) (2014) 142-153.
DOI:10.1158/2326-6066.CIR-13-0031-T

M.R. Mirza, L. Tandaric, J.R. Henriksen, et al., NSGO-OV-UMB1/ENGOT-OV30:
A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody
Oleclumab in patients with relapsed ovarian cancer. Gynecol Oncol 188 (2024) 103-110.
DOI:10.1016/j.ygyno.2024.06.017

762 [16] M. Uhlen, L. Fagerberg, B.M. Hallstrom, et al., Proteomics. Tissue-based map of
763 the human proteome. Science 347(6220) (2015) 1260419.
764 DOI:10.1126/science.1260419

[17] M. Uhlen, C. Zhang, S. Lee, et al., A pathology atlas of the human cancer
 transcriptome. Science 357(6352) (2017). DOI:10.1126/science.aan2507

[18] M. Turcotte, K. Spring, S. Pommey, et al., CD73 is associated with poor prognosis
in high-grade serous ovarian cancer. Cancer Res 75(21) (2015) 4494-4503.
DOI:10.1158/0008-5472.CAN-14-3569

[19] F. Ghiringhelli, M. Bruchard, F. Chalmin, et al., Production of adenosine by
ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012
(2012) 473712. DOI:10.1155/2012/473712

[20] S. Chen, D.A. Wainwright, J.D. Wu, et al., CD73: an emerging checkpoint for
cancer immunotherapy. Immunotherapy 11(11) (2019) 983-997. DOI:10.2217/imt-20180200

776 [21] C.M. Hay, E. Sult, Q. Huang, et al., Targeting CD73 in the tumor
777 microenvironment with MEDI9447. Oncoimmunology 5(8) (2016) e1208875.
778 DOI:10.1080/2162402X.2016.1208875

779 [22] M. Moller, V. Orth, V. Umansky, et al., Myeloid-derived suppressor cells in 780 peripheral blood as predictive biomarkers in patients with solid tumors undergoing

immune checkpoint therapy: systematic review and meta-analysis. Front Immunol 15(2024) 1403771. DOI:10.3389/fimmu.2024.1403771

[23] K. Okla, A. Czerwonka, A. Wawruszak, et al., Clinical Relevance and
Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived
Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. Front Immunol 10 (2019) 691.
DOI:10.3389/fimmu.2019.00691

- [24] E.R. Zunder, R. Finck, G.K. Behbehani, et al., Palladium-based mass tag cell
 barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat
 Protoc 10(2) (2015) 316-333. DOI:10.1038/nprot.2015.020
- 790 [25] S. Granjeaud. cytoBatchNorm. 2022; <u>https://github.com/i-cyto/cytoBatchNorm</u>.
 791 (Accessed: 01. Sep. 2024)
- [26] S. Van Gassen, B. Callebaut, M.J. Van Helden, et al., FlowSOM: Using selforganizing maps for visualization and interpretation of cytometry data. Cytometry A 87(7)
 (2015) 636-645. DOI:10.1002/cyto.a.22625
- [27] E. Becht, L. McInnes, J. Healy, et al., Dimensionality reduction for visualizing
 single-cell data using UMAP. Nat Biotechnol (2018). DOI:10.1038/nbt.4314
- [28] H. Crowell, V. Zanotelli, S. Chevrier, et al. CATALYST: Cytometry dATa anALYSis
 Tools. R package version 1.28.0. 2024; <u>https://github.com/HelenaLC/CATALYST</u>.
 (Accessed: 01. Sep. 2024)
- L.M. Weber, M. Nowicka, C. Soneson, et al., diffcyt: Differential discovery in high dimensional cytometry via high-resolution clustering. Commun Biol 2 (2019) 183.
 DOI:10.1038/s42003-019-0415-5
- 803 [30] B. Mastelic-Gavillet, B. Navarro Rodrigo, L. Decombaz, et al., Adenosine 804 mediates functional and metabolic suppression of peripheral and tumor-infiltrating 805 CD8(+) T cells. J Immunother Cancer 7(1) (2019) 257. DOI:10.1186/s40425-019-0719-5
- [31] Y. Li, Z. Zhang, Y. Hu, et al., Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR)
 May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients
 Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 10 (2020) 654.
 DOI:10.3389/fonc.2020.00654
- [32] J.T. Cohen, T.J. Miner, M.P. Vezeridis. Is the neutrophil-to-lymphocyte ratio a
 useful prognostic indicator in melanoma patients? Melanoma Manag 7(3) (2020)
 MMT47. DOI:10.2217/mmt-2020-0006

[33] C. Krieg, M. Nowicka, S. Guglietta, et al., High-dimensional single-cell analysis
predicts response to anti-PD-1 immunotherapy. Nat Med 24(2) (2018) 144-153.
DOI:10.1038/nm.4466

[34] K. Okla. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking
Back and Forward. Cells 12(14) (2023). DOI:10.3390/cells12141912

818 [35] P. Kongsted, T.H. Borch, E. Ellebaek, et al., Dendritic cell vaccination in 819 combination with docetaxel for patients with metastatic castration-resistant prostate 820 cancer: A randomized phase II study. Cytotherapy 19(4) (2017) 500-513. 821 DOI:10.1016/j.jcyt.2017.01.007

[36] C. Meyer, L. Cagnon, C.M. Costa-Nunes, et al., Frequencies of circulating MDSC
correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer
Immunol Immunother 63(3) (2014) 247-257. DOI:10.1007/s00262-013-1508-5

[37] G. Enblad, H. Karlsson, G. Gammelgard, et al., A Phase I/IIa Trial Using CD19Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res
24(24) (2018) 6185-6194. DOI:10.1158/1078-0432.CCR-18-0426

[38] K. Li, H. Shi, B. Zhang, et al., Myeloid-derived suppressor cells as
immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct
Target Ther 6(1) (2021) 362. DOI:10.1038/s41392-021-00670-9

[39] Y. Berckmans, Y. Hoffert, A. Vankerckhoven, et al., Drug Repurposing for
Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian
Cancer: A Literature Review of Potential Candidates. Pharmaceutics 15(7) (2023).
DOI:10.3390/pharmaceutics15071792

[40] J. Li, L. Wang, X. Chen, et al., CD39/CD73 upregulation on myeloid-derived
suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung
cancer. Oncoimmunology 6(6) (2017) e1320011. DOI:10.1080/2162402X.2017.1320011

838[41]L. Antonioli, P. Pacher, E.S. Vizi, et al., CD39 and CD73 in immunity and839inflammation.TrendsMolMed19(6)(2013)355-367.840DOI:10.1016/j.molmed.2013.03.005

[42] B. Diskin, S. Adam, M.F. Cassini, et al., PD-L1 engagement on T cells promotes
self-tolerance and suppression of neighboring macrophages and effector T cells in
cancer. Nat Immunol 21(4) (2020) 442-454. DOI:10.1038/s41590-020-0620-x

[43] Y. Zheng, L. Han, Z. Chen, et al., PD-L1(+)CD8(+) T cells enrichment in lung
cancer exerted regulatory function and tumor-promoting tolerance. iScience 25(2) (2022)
103785. DOI:10.1016/j.isci.2022.103785

[44] J. Bendell, P. LoRusso, M. Overman, et al., First-in-human study of oleclumab, a
potent, selective anti-CD73 monoclonal antibody, alone or in combination with
durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother 72(7)
(2023) 2443-2458. DOI:10.1007/s00262-023-03430-6

[45] N. Bach, R. Winzer, E. Tolosa, et al., The Clinical Significance of CD73 in Cancer.
Int J Mol Sci 24(14) (2023). DOI:10.3390/ijms241411759

[46] H.K. Oh, J.I. Sin, J. Choi, et al., Overexpression of CD73 in epithelial ovarian
carcinoma is associated with better prognosis, lower stage, better differentiation and
lower regulatory T cell infiltration. J Gynecol Oncol 23(4) (2012) 274-281.
DOI:10.3802/jgo.2012.23.4.274

[47] Y. Fujiwara, S. Kato, D. Nishizaki, et al., High indoleamine 2,3-dioxygenase
transcript levels predict better outcome after front-line cancer immunotherapy. iScience
27(4) (2024) 109632. DOI:10.1016/j.isci.2024.109632

860 [48] I. Hoffmann, M.P. Dragomir, N. Monje, et al., Increased expression of IDO1 is 861 associated with improved survival and increased number of TILs in patients with high-Neoplasia 44 (2023)100934. 862 grade serous ovarian cancer. 863 DOI:10.1016/j.neo.2023.100934

[49] J.E. Kenison, Z. Wang, K. Yang, et al., The aryl hydrocarbon receptor suppresses
immunity to oral squamous cell carcinoma through immune checkpoint regulation. Proc
Natl Acad Sci U S A 118(19) (2021). DOI:10.1073/pnas.2012692118

[50] A. Amobi-McCloud, R. Muthuswamy, S. Battaglia, et al., IDO1 Expression in
Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Front
Immunol 12 (2021) 678999. DOI:10.3389/fimmu.2021.678999

870

871 FIGURE AND TABLE CAPTIONS

Figure 1 Trial overview, sample collection and processing. (A) Schema of the patient disposition and immunotherapy administration schedule of the NSGO-OV-UMB1/ENGOT-OV30 trial. One treatment cycle had a duration of four weeks. (B) Blood sample acquisition and processing workflow (full protocol provided in the online supplemental appendix). (C) Swimmer plot illustrating the duration of treatment and observation for each patient included in this study, as well as blood sampling timepoints.

879

878

IV – intravenous

880 **Online supplemental table S1** The 40-marker mass cytometry panel used for 881 immunophenotyping in this study. *Titrated on both non-stimulated leukocytes and 882 stimulated PBMCs; [†]Titrated on stimulated PBMCs; [‡]Intracellular target; [§]Conjugated in-883 house

884

885 **Online supplemental figure S1** Cleanup gating workflow used for the refinement of 886 the raw cytometry by time-of-flight (CyTOF) data into intact single cells (singlets).

887

Formation and overall view of the study dataset. (A) Heatmap of the 888 Figure 2 normalized median expression of the 13 markers (rows) used for the clustering of total 889 890 leukocytes. Each column represents a cluster. Appropriateness of leukocyte subset 891 assignment* was confirmed by unsupervised hierarchical clustering (visualized above heatmap). (B) Heatmap of the normalized median expression of the 22 markers (rows) 892 893 used for the clustering of PBMCs. Each column represents a leukocyte subset. Subset 894 assignment* was performed and validated in the same manner as for the total leukocyte clusters. (C) UMAP projection of an aggregated sample of PBMCs, consisting of an 895 equal number of cells sampled from each blood sample. Each cell is colored by subset 896 897 assignment^{*}. (D) Overview of the leukocyte (upper stacked bar plots) and PBMC (lower 898 stacked bar plots) composition of all blood samples (detailed composition of each 899 sample is given in online supplemental table S2). *Leukocyte subset assignment coloring is consistent throughout figure 2. TCRgd - gamma-delta T-cell receptor 900

901

902 **Table 1** Characteristics of the included patients.

903

904 Figure 3 Significant differences, changes, and trends in the relative abundances of leukocyte populations. (A) Comparison of the relative baseline abundances of 905 906 granulocytes and total PBMCs between survival duration groups (short-term survival is 907 defined as observed survival of at most 16 weeks since the start of treatment; long-term 908 survival is defined as observed survival of more than 16 weeks since the start of treatment). Symbols representing each patient are consistent throughout all figures. (B) 909 910 UMAP projections of aggregated baseline samples of total leukocytes stratified by 911 survival duration group. Both projections consist of the same number of cells. The significant difference in the density of the total PBMC subset between groups is 912 913 accented with a dashed blue outline. (C) Changes in the relative abundances of 914 classical monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) during 915 treatment in the group of long-term survivors (n=7). The two PBMC subsets composed 916 of CD14⁺CD16⁻ myeloid cells (Monocytes - Classical and M-MDSCs), are shown 917 separately in the left and middle panel. The level of HLA-DR expression forms the basis for the separation of classical monocytes (HLA-DR^{+/hi}) from M-MDSCs (HLA-DR^{-/lo}) 918 919 (online supplemental figure S2). In the right panel, the classical monocyte and M-MDSC 920 subsets were merged to illustrate the significant and continued increase of the abundance of CD14⁺CD16⁻ myeloid cells during treatment. (D) UMAP projections of 921 aggregated PBMC samples from the long-term survivors (n=7), stratified by treatment 922

timepoint. Cells of the "Monocytes-Classical" and "M-MDSCs" subsets are delineated 923 with a blue outline. (E) Changes in the relative abundances of M-MDSCs during 924 925 treatment. Patients were stratified into rapid progressors (progression confirmed after at 926 most 16 weeks since the start of treatment) and slow progressors (progression 927 confirmed after more than 16 weeks since the start of treatment). (F) Changes in the relative abundances of central memory (CM) T-cell subsets during treatment. Patients 928 were stratified into rapid- and slow progressors. (G) Comparison of the relative 929 930 abundances of M-MDSCs in samples collected at blood sampling timepoints 931 immediately before and after confirmation of disease progression. ns - not significant: * p_{adi} < 0.05; *** - p_{adi} < 0.001 932

933

Online supplemental figure S2 Determination of the cutoff of HLA-DR expression for the separation of classical monocytes and myeloid monocyte-derived suppressor cells. (A) The subset of naïve CD4⁺ T cells was used as a negative control for HLA-DR expression. (B) The subset of naïve B cells was used as a positive control for HLA-DR expression. (C) The cutoff of HLA-DR expression for the separation of the cells of the CD14⁺CD16⁻ myeloid cell subset was set according to the optimal expression cutoffs in the negative and positive control subsets.

941

942 **Online supplemental table S2** Detailed sample composition data.

Figure 4 Significant changes in cell state marker expression during treatment. (A) 944 Heatmaps of the top significant differences in the relative state marker expression in 945 946 long-term survivor samples taken at baseline (n=7) (left half of the heatmaps) and after 947 either two (right half of left heatmap) or four treatment cycles (right half of right 948 heatmap). Each row of the heatmap is labeled with the combination of marker (left) and subset (right, in brackets) it represents, sorted from top to bottom based on increasing p-949 value. (B) Median arcSinh(5)-transformed expression of PD-L1 over time for all T-cell 950 951 subsets in the long-term survivor (n=7) samples. The trendline was calculated using 952 simple linear regression. * - p_{adi} < 0.05; CM - central memory; E - effector; EM - effector 953 memory; GranB - granzyme B; logFC - log₂(fold change); Mono - monocytes; N - naïve; NC - non-classical; NK-56 - CD56+++ NK cells; NKT - NKT cells; ns - not significant; T-954 CD4 - CD4⁺ T cells; T-CD8 - CD8⁺ T cells; T-DN - CD4⁻CD8⁻ (double-negative) T cells; 955 956 Tgd - gamma-delta T cells

957

958 Figure 5 Correlations between progression-free survival duration and either the 959 relative leukocyte subset abundances or state marker expression levels at baseline for 960 long-term survivors (n=7). (A) Heatmap showing correlation analysis results (online 961 supplemental table S3). Pearson or Spearman correlation analysis was selected based on the normality of the dataset, assessed using the Shapiro-Wilk test. (B) Plots depicting 962 963 significant correlations between transformed median CD73 expression at baseline and 964 time to progression. Symbols representing each patient are consistent throughout Fig. 5. 965 (C) Plots illustrating most significant correlations between transformed median IDO1 966 expression at baseline and time to progression. |r| - absolute value of Pearson's

967	correlation coefficient; $ \rho $ - absolute value of Spearman's correlation coefficient; GranB -	
968	granzyme B	
969		
970	Online supplemental table S3	Full correlation testing results.
971		
972	Online supplemental table S4	Results of correlation testing between IDO1 and PD-

L1 expression at baseline. 973

















